$PFE down 7% after saying Friday its Phase 3 ``Pallas'' study of Ibrance is unlikely to meet its endpoint. Sentiment on the name had been turning, but now analysts and investors pointing toward a need for deals to fill the growth gap the failure is leaving. More on @TheTerminal